(Reuters) – Britain’s GSK released new data on Tuesday from early-stage studies, citing that its antibody-based COVID-19 therapy with U.S. partner Vir is effective against all mutations of the new Omicron coronavirus variant.
The data, yet to be published in a peer-reviewed medical journal, shows that the companies’ treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Sherry Jacob-Phillips)
